Metformin in Safety and Efficacy in Gouty Patients

Mostafa Bahaa

Status and phase

Not yet enrolling

Phase 2

Conditions

Gout

Treatments

Other: placebo

Drug: Metformin

Study type

Interventional

Funder types

Other

Identifiers

NCT06924658

8746

Details and patient eligibility

About

The most frequent crystal arthropathy is gout, which is also the most prevalent cause of inflammatory arthritis. Gouty Patients frequently have excruciating pain and swelling in their joints. Gout is linked to decreased health-related quality of life and functional disability. Gout and its associated diseases have been shown to have a significant impact on patients mortality and morbidities. Metformin, a biguanide, is used to manage diabetes by reducing insulin resistance and preventing comorbidities such as cerebrovascular and coronary artery disease, as well as providing renal protection to diabetic nephropathy patients

Enrollment

70 estimated patients

Sex

All

Ages

18 to 60 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Gouty patients clinically diagnosed as gouty arthritis based on the American College of Rheumatology/European League Against Rheumatism criteria of gout.

Exclusion criteria

Systemic disorders such as cardiovascular, neurological, coronary artery disease.
Hypertension, hyperlipidemia, diabetes mellitus, active infections.
Other inflammatory or autoimmune diseases.
Patients on biologics,
Cases with hypersensitivity to metformin and those with impaired liver and kidney functions.